Literature DB >> 31880741

Chlamydia trachomatis and Neisseria gonorrhoeae Retesting and Reinfection Rates in New Zealand Health Care Settings: Implications for Sexually Transmitted Infection Control.

Sally B Rose1, Susan M Garrett1, James Stanley2, Susan R H Pullon1.   

Abstract

BACKGROUND: Reinfection with chlamydia or gonorrhea is common and can lead to significant reproductive health complications so testing for reinfection after treatment is recommended. This study described retesting and reinfection rates in regions of New Zealand with higher-than-average population rates of chlamydia.
METHODS: This retrospective cohort study analyzed chlamydia and gonorrhea testing data from 2 laboratories providing community testing services for 4 higher-rate regions in the North Island of New Zealand. Three years of data were obtained (2015-2017) to include a minimum of 6-month follow-up for all individuals. Retesting and reinfection rates between 6 weeks and 6 months of a positive result were calculated, and time to retesting was plotted using Kaplan-Meier curves. Logistic regression modeling was used to determine the odds of retesting (outcome 1) and reinfection (outcome 2) between 6 weeks and 6 months of follow-up.
RESULTS: Overall, 34% (3151/9241) of the cohort was retested within the recommended period, of whom 21% retested positive. Significant differences were observed in the odds of retesting by sex, age band, ethnic group, clinic type, and region (P < 0.01). The odds of a subsequent positive on retesting within 6 months differed significantly by sex, age band, and ethnic group (P < 0.01).
CONCLUSIONS: These findings reflect substantial gaps in the delivery of best-practice sexually transmitted infection management in New Zealand. There is a clear need to prioritize the implementation of clinic-level processes to support clinicians in the routine delivery of best-practice sexual health care. These should include routine provision of patient advice about retesting and strategies to promote timely and equitable access to retesting.

Entities:  

Year:  2020        PMID: 31880741     DOI: 10.1097/OLQ.0000000000001112

Source DB:  PubMed          Journal:  Sex Transm Dis        ISSN: 0148-5717            Impact factor:   2.830


  4 in total

1.  Rates of Appropriate Treatment and Follow-Up Testing After a Gonorrhea and/or Chlamydia Infection in an Urban Network of Federally Qualified Health Center Systems.

Authors:  Laura McWhirter; Yingbo Lou; Sarah Reingold; Sarah Warsh; Tara Thomas-Gale; Christine Haynes; Deborah Rinehart; Karen A Wendel; Holly M Frost
Journal:  Sex Transm Dis       Date:  2022-01-10       Impact factor: 3.868

2.  Global epidemiology of Neisseria gonorrhoeae in infertile populations: systematic review, meta-analysis and metaregression.

Authors:  Hiam Chemaitelly; Alzahraa Majed; Farah Abu-Hijleh; Karel Blondeel; Thabo Christopher Matsaseng; James Kiarie; Igor Toskin; Laith J Abu-Raddad
Journal:  Sex Transm Infect       Date:  2020-05-18       Impact factor: 3.519

3.  Incidence and risk factors of gonococcal urethritis reinfection among Thai male patients in a multicenter, retrospective cohort study.

Authors:  Monai Meesaeng; Boonsub Sakboonyarat; Supitchaya Thaiwat
Journal:  Sci Rep       Date:  2021-11-26       Impact factor: 4.379

4.  Synthetic DNA Delivery of an Optimized and Engineered Monoclonal Antibody Provides Rapid and Prolonged Protection against Experimental Gonococcal Infection.

Authors:  Elizabeth M Parzych; Sunita Gulati; Bo Zheng; Mamadou A Bah; Sarah T C Elliott; Jacqueline D Chu; Nancy Nowak; George W Reed; Frank J Beurskens; Janine Schuurman; Peter A Rice; David B Weiner; Sanjay Ram
Journal:  mBio       Date:  2021-03-16       Impact factor: 7.867

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.